After signing up, you'll start to receive regular news updates from us.
UCB Launches Strategic Research Alliance with Weill-Cornell Medical College
Complete the form below to unlock access to ALL audio articles.
UCB has announced that it has launched a major strategic research alliance with Weill-Cornell Medical College that aims to convert scientific discovery into transformative health improvements in areas of high patient need.
This research alliance reflects UCB’s belief that science progresses more rapidly when innovation is fostered by strong partnerships with leading academic partners.
UCB will provide funding for three translational research programs over three years in the areas of bone disorders, metabolic disease and rare genetic variant analysis led respectively by Dr. Laurie H. Glimcher, the Stephen and Suzanne Weiss Dean of Weill-Cornell Medical College, Dr. Timothy McGraw, Professor of Biochemistry, and Dr. Ronald Crystal, Chairman of Genetic Medicine.
The research programs are aligned with a key strategy of UCB NewMedicines™ to focus on the discovery of medicines targeting pathways with a high level of genetic and human validation.
Ismail Kola, Executive Vice President, UCB & President, New Medicines, UCB said, “No single organization can work alone to translate cutting-edge fundamental scientific research into transformative medicines for people with severe disease. That is why are creating a super network with trusted scientific partners globally, combining knowledge of patient medical need with understanding of disease mechanisms. This strategic research alliance brings together Weill Cornell’s world class academic research with our discovery team with the shared objective of developing medicines that could transform the lives of people with severe diseases.”
“We are thrilled to enter into this strategic alliance with UCB to drive research discoveries made at the bench into the most advanced treatments for patients in the clinic,” Dr. Glimcher said. “UCB has an accomplished track record of developing first-rate treatments and therapies. With complementary expertise and a common mission - to help patients, improve health and save lives - our alliance will demonstrate the power of academic-industry collaboration.”
